Consolidation Doublet Therapy:

Phase 2Small molecule

Consolidation Doublet Therapy: is one of 38 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholangiocarcinomaRecruiting

Intrahepatic CholangiocarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

44 competitors in Intrahepatic Cholangiocarcinoma

#DrugCompanyPhaseTrials

Lenvima

Eisai

Approved

9 2

Alkeran

Paraplatin

Velcade

SShilpa Grover, MD, MPH

Gemzar

12 6

Imfinzi

AstraZeneca

Phase 2

9 7

Eloxatin

Teva

Phase 2

3 8

Beyfortus

BeiGene

Phase 2

3 9

Fudr

Pfizer

Phase 2

3 10

Pemazyre

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Intrahepatic Cholangiocarcinoma

NCT05422690

Clinical

Trials by Indication[1]

Intrahepatic Cholangiocarcinoma1 trial

A Phase II Single-center, Open-label, Single Arm Study of Induction Gemcitabine, Cisplatin and Durvalumab Followed by Gemcitabine, Cisplatin and Yttrium-90 (Y-90) Radioembolization for the Treatment of Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma

Recruiting·IInova Health Care Services·Phase 2·NCT05422690·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Consolidation Doublet Therapy:. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Consolidation Doublet Therapy: compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Consolidation Doublet Therapy:. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inova Health Care Services company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInova Health Care Services

Consolidation Doublet Therapy:

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Intrahepatic Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News